The Effects of Systemic Isotretinoin Treatment on Adrenal Steroid and Sex Hormones Level in Severe Acne Vulgaris

Sponsor
Marmara University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05903716
Collaborator
(none)
40
1
9.5
4.2

Study Details

Study Description

Brief Summary

Acne vulgaris is a chronic inflammatory skin disease involving the pilosebaceous unit, affecting approximately 95% of adolescents and young adults.

Follicular hyperkeratinization, increased sebum production, androgen hormones and inflammation play a role in the pathogenesis of acne. Androgens (Testosterone, DHEA-S and DHT) play a role in the development of acne, hypertrophy of the sebaceous glands and increased sebum production. Androgen receptors are located in the basal layer of the sebaceous glands keratinocytes and they are located in the outer sheath of the hair follicle. These receptors are responsible for the proliferative action of keratinocytes.

The relationship between androgen hormones and acne in women and prepubertal children is well known. Many studies have shown a strong association between acne and hyperandrogenism in women.

Systemic isotretinoin therapy can be used in patients with severe acne vulgaris who do not respond to topical and oral antibiotic treatments.

In recent studies, it has been shown that systemic isotretinoin used in acne treatment changes many hormones such as GnRH, FSH, LH, Estrogen, Progesterone, Testosterone, TSH, T4 and Prolactin and causes side effects such as menstrual irregularity and hirsutism.

However, data on the effect of oral isotretinoin on adrenal and sex hormones are contradictory.

In this study, it was aimed to evaluate the effect of oral isotretinoin on adrenal steroid and sex hormone levels and to compare it with a healthy control.

Isotretinoin treatment is started in acne vulgaris patients at a dose of 0.5-0.8mg/kg/day. The total cumulative dose is 120 mg/kg.

At baseline and at the 3rd month of isotretinoin treatment, 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated with LCMS/MS technique.

In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated by ELISA method.

In the baseline 2nd, 3rd, 4th and 6th months of the treatment and 3 months after the treatment, the patients' height, weight, body mass index measurements, VAS scoring of patient treatment satisfaction, Global Acne Severity Score, Acne Quality of Life Score, and Modified Ferriman Gallwey Score for hirsutism will be recorded.

The side effects of isotretinoin such as menstrual irregularity, increased hair growth, and cheilitis, dryness of the oral mucosa, skin dryness, dermatitis seen in patients during treatment will be recorded.

*Hormone tests were performed on 2th and 3rd days of menstruation

Condition or Disease Intervention/Treatment Phase

Study Design

Study Type:
Observational
Anticipated Enrollment :
40 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
The Effects of Systemic Isotretinoin Treatment on Adrenal Steroid and Sex Hormones Level in Severe Acne Vulgaris
Actual Study Start Date :
Sep 15, 2022
Anticipated Primary Completion Date :
Jun 30, 2023
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Severe acne vulgaris

40 female patients aged 14-20 years, who were diagnosed with severe to moderate acne bulgaris and will be treated with isotretinoin.

Diagnostic Test: Hormone
At baseline 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated.In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated from all patients

Drug: Isotretinoin
İn the 3rd month of isotretinoin treatment, 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated.In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated by ELISA method

Healthy control

40 female patients aged 14-20 years

Diagnostic Test: Hormone
At baseline 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated.In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated from all patients

Outcome Measures

Primary Outcome Measures

  1. FSH Level [Baseline (Before isotretinoin treatment)]

    Evaluation FSH levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  2. FSH Level [3rd month of isotretinoin treatment]

    Evaluation FSH levels in after 3 month of isotretinoin treatment

  3. LH Level [Baseline (Before isotretinoin treatment)]

    Evaluation LH levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  4. LH Level [3rd month of isotretinoin treatment]

    Evaluation LH levels after 3 month of isotretinoin treatment

  5. Prolactin Level [Baseline (Before isotretinoin treatment)]

    Evaluation Prolactin levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  6. Prolactin Level [3rd month of isotretinoin treatment]

    Evaluation Prolactin levels after 3 month of isotretinoin treatment

  7. Estrogen Level [Baseline (Before isotretinoin treatment)]

    Evaluation Estrogen levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  8. Estrogen Level [3rd month of isotretinoin treatment]

    Evaluation Estrogen levels after 3 month of isotretinoin treatment

  9. Testosterone Level [Baseline (Before isotretinoin treatment)]

    Evaluation Testosterone levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  10. Testosterone Level [3rd month of isotretinoin treatment]

    Evaluation Testosterone levels after 3 month of isotretinoin treatment

  11. Free-Testosterone Level [Baseline (Before isotretinoin treatment)]

    Evaluation Free-Testosterone levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  12. Free-Testosterone Level [3rd month of isotretinoin treatment]

    Evaluation Free-Testosterone levels after 3 month of isotretinoin treatment

  13. DHEA-s Level [Baseline (Before isotretinoin treatment)]

    Evaluation DHEA-s levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  14. DHEA-s Level [3rd month of isotretinoin treatment]

    Evaluation DHEA-s levels after 3 month of isotretinoin treatment

  15. SHBG Level [Baseline (Before isotretinoin treatment)]

    Evaluation SHBG levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  16. SHBG Level [3rd month of isotretinoin treatment]

    Evaluation SHBG levels after 3 month of isotretinoin treatment

  17. TSH Level [Baseline (Before isotretinoin treatment)]

    Evaluation TSH levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  18. TSH Level [3rd month of isotretinoin treatment]

    Evaluation TSH levels iafter 3 month of isotretinoin treatment

  19. T4 Level [Baseline (Before isotretinoin treatment)]

    Evaluation T4 levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  20. T4 Level [3rd month of isotretinoin treatment]

    Evaluation T4 levels after 3 month of isotretinoin treatment

  21. 17-OH Progesteroone Level [Baseline (Before isotretinoin treatment)]

    Evaluation 17-OH Progesteroone levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  22. 17-OH Progesteroone Level [3rd month of isotretinoin treatment]

    Evaluation 17-OH Progesteroone after 3 month of isotretinoin treatment

  23. DHEA(LCMS) Level [Baseline (Before isotretinoin treatment)]

    Evaluation DHEA(LCMS) levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  24. DHEA(LCMS) Level [3rd month of isotretinoin treatment]

    Evaluation DHEA(LCMS) levels after 3 month of isotretinoin treatment

  25. DHEA-S(LCMS) Level [Baseline (Before isotretinoin treatment)]

    Evaluation DHEAS(LCMS) levels in Severe Acne Vulgaris patient Before isotretinoin treatmen

  26. DHEA-S(LCMS) Level [3rd month of isotretinoin treatment]

    Evaluation DHEAS(LCMS) levels after 3 month of isotretinoin treatment

  27. Androstenedione Level [Baseline (Before isotretinoin treatment)]

    Evaluation Androstenedione levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  28. Androstenedione Level [3rd month of isotretinoin treatment]

    Evaluation Androstenedione levels after 3 month of isotretinoin treatment

  29. Aldosterone Level [Baseline (Before isotretinoin treatment)]

    Evaluation Aldosterone levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  30. Aldosterone Level [3rd month of isotretinoin treatment]

    Evaluation Aldosterone levels after 3 month of isotretinoin treatment

  31. Testosterone(LCMS) Level [Baseline (Before isotretinoin treatment)]

    Evaluation Testosterone(LCMS) levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  32. Testosterone(LCMS) Level [3rd month of isotretinoin treatment]

    Evaluation Testosterone(LCMS) levels after 3 month of isotretinoin treatment

  33. Dihydrotestosterone Level [Baseline (Before isotretinoin treatment)]

    Evaluation Dihydrotestosterone levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  34. Dihydrotestosterone Level [3rd month of isotretinoin treatment]

    Evaluation Dihydrotestosterone levels after 3 month of isotretinoin treatment

  35. Estradiol Level [Baseline (Before isotretinoin treatment)]

    Evaluation Estradiol levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  36. Estradiol Level [3rd month of isotretinoin treatment]

    Evaluation Estradiol levels after 3 month of isotretinoin treatment

  37. 17-OH Pregnenolone Level [Baseline (Before isotretinoin treatment)]

    Evaluation 17-OH Pregnenolone levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  38. 17-OH Pregnenolone Level [3rd month of isotretinoin treatment]

    Evaluation 17-OH Pregnenolone levels after 3 month of isotretinoin treatment

  39. Androsterone Level [Baseline (Before isotretinoin treatment)]

    Evaluation Androsterone levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  40. Androsterone Level [3rd month of isotretinoin treatment]

    Evaluation Androsterone levels after 3 month of isotretinoin treatment

  41. Cortisol Level [Baseline (Before isotretinoin treatment)]

    Evaluation Cortisol levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  42. Cortisol Level [3rd month of isotretinoin treatment]

    Evaluation Cortisol levels after 3 month of isotretinoin treatment

  43. Corticosterone Level [Baseline (Before isotretinoin treatment)]

    Evaluation Corticosterone levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  44. Corticosterone Level [3rd month of isotretinoin treatment]

    Evaluation Corticosterone after 3 month of isotretinoin treatment

  45. 11-Deoxycortisol Level [Baseline (Before isotretinoin treatment)]

    Evaluation 11-Deoxycortisol levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  46. 11-Deoxycortisol Level [3rd month of isotretinoin treatment]

    Evaluation 11-Deoxycortisol levels after 3 month of isotretinoin treatment

  47. Progesterone(LCMS) Level [Baseline (Before isotretinoin treatment)]

    Evaluation Progesterone(LCMS) levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  48. Progesterone(LCMS) Level [3rd month of isotretinoin treatment]

    Evaluation Progesterone(LCMS) levels after 3 month of isotretinoin treatment

  49. 21-Deoxycortisololone Level [Baseline (Before isotretinoin treatment)]

    Evaluation 21-Deoxycortisololone levels in Severe Acne Vulgaris patient Before isotretinoin treatment

  50. 21-Deoxycortisololone Level [3rd month of isotretinoin treatment]

    Evaluation 21-Deoxycortisololone levels after 3 month of isotretinoin treatment

  51. 11-Deoxycortisolone Level [Baseline (Before isotretinoin treatment)]

    Evaluation 11-Deoxycortisolone levels in Severe Acne Vulgaris patient Before isotretinoin treatmen

  52. 11-Deoxycortisolone Level [3rd month of isotretinoin treatment]

    Evaluation 11-Deoxycortisolone levels after 3 month of isotretinoin treatment

  53. Pregnenolone Level [Baseline (Before isotretinoin treatment)]

    Evaluation Pregnenolone levels in Severe Acne Vulgaris patient Before isotretinoin treatmen

  54. Pregnenolone Level [3rd month of isotretinoin treatment]

    Evaluation Pregnenolone levels after 3 month of isotretinoin treatment

Secondary Outcome Measures

  1. Comparison of hormone levels in acne vulgaris patients and healthy group [Baseline]

    Comparison of all hormone levels in acne vulgaris patients and healthy group

  2. Menstrual İrregularity [2. 4. 6. months and 3 month after treatment]

    Evaluation of side effects such as menstrual irregularity that can be seen due to isotretinoin

  3. Relationship between Menstrual irregularity and hormone levels [3rd month of isotretinoin treatment]

    Evaluation of the relationship between menstrual irregularity and changes in hormone levels

Eligibility Criteria

Criteria

Ages Eligible for Study:
14 Years to 20 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Severe to moderate acne vulgaris

  • 14 - 20 Years old

  • Female patients

Exclusion Criteria:
  • Male patients

  • Patients who received vitamin A or hormone therapy in the last 3 months

  • Those with adrenal, thyroid, pituitary gland disease

  • Those with psychiatric disorders

  • History of drug use that causes acneiform eruption (eg, corticosteroids…)

  • Acne conglobata and acne fulminans

Contacts and Locations

Locations

Site City State Country Postal Code
1 Marmara University School of Medicine,Department of Dermatology. Istanbul Turkey

Sponsors and Collaborators

  • Marmara University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Marmara University
ClinicalTrials.gov Identifier:
NCT05903716
Other Study ID Numbers:
  • 09.2022.464
First Posted:
Jun 15, 2023
Last Update Posted:
Jun 15, 2023
Last Verified:
Jun 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Marmara University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 15, 2023